• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 4
  • 2
  • 1
  • Tagged with
  • 8
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
1

Medication use patterns of antiepileptics and epileptic events

Shcherbakova, Natalia G., 1982- 23 October 2012 (has links)
The purpose of this study was to identify clinical and demographic predictors of seizure recurrence in medically-treated patients with epilepsy. Innovus Invision™ Data Mart insurance claims from January 1, 2007 to September 30, 2010 were retrospectively analyzed. Patients aged 18-64 years with a primary or secondary diagnosis of epilepsy and >1 prescription claim for an antiepileptic drug (AED) pre-index were included. The primary outcome was incidence of seizures defined as an occurrence of an emergency room visit, ambulance service use or hospitalization with a primary or secondary diagnosis of epilepsy during the 1-year follow-up period. Predictor variables included antiepileptic drug (AED) adherence (Proportion of Days Covered ≥ 80 %), general comorbidity (Charlson’s Comorbidity Index ≥ 1), any mental health comorbidity, evidence of a prior seizure, type of epilepsy diagnosis (intractable versus non-intractable), presence of AED-interacting medications and any bioequivalent AED switch. The covariates included age, gender and geographic region of residence. The overall incidence of post-index seizures in the 1-year follow-up period for all four monotherapy cohorts combined was 5.3 % (n=166/3140), but was higher for the Keppra®/levetiracetam cohort (7.9%; n=88/1114) compared to the other cohorts [Lamictal®/lamotrigine (3.9%; n=45/1143), Trileptal®/oxcarbazepine (4.0%; n=18/456) and Topamax®/topiramate (3.5%; n=15/427)]. The combined cohort analysis demonstrated that pre-index seizures (odds ratio [OR] = 4.28; 95% CI, 2.81-6.53), any mental health comorbidity ([OR] = 3.41; 95% CI, 2.10-5.54), Charlson comorbidity Index ≥1 ([OR] = 2.88; 95% CI, 1.96-4.24) and monotherapy with Keppra®/levetiracetam ([OR] = 1.54; 95% CI, 1.03-2.31) were significant predictors of seizure recurrence. Among covariates, only geographic region was a significant predictor, with patients residing in the Northeast U.S. having higher odds of post-index seizure ([OR] = 1.92; 95% CI, 1.19-3.10), while controlling for clinical, medication and demographic characteristics. A bioequivalent AED switch, type of epilepsy diagnosis, AED adherence and the presence of interacting medications were not significant predictors of seizure recurrence in the combined cohort (p>0.05). Results indicate that epilepsy patients with comorbid conditions (both mental and somatic diseases), as well as patients who may have initially been unstable (with previous seizure occurrences) were more likely to experience seizures during the follow-up period. / text
2

Artemisinin-Based Combination Anti-malarials Do Not Enhance Anti-melanoma Activity of Artemisinin-Monotherapy

Jacobs, Suesan, Vonderfecht, Amanda, Wondrak, Georg January 2013 (has links)
Class of 2013 Abstract / Specific Aims: To determine if melanoma cells are more vulnerable to Amodiaquine (AQ) or Lumefantrine (LF)-based artemisinin combination therapy compared to artemisinin monotherapy. Methods: Tested anti-malarials in vitro for anti-melanoma activity, which contained 100,000 of the A375 human metastatic melanoma cells that were repeatedly treated independently three times. Main Results: Dihydroartemisinin (DHA) monotherapy induced significant cell death in melanoma cells. However, artemisinin combination therapy (ACT) did not enhance DHA-induced cell death. AQ protected against DHA-induced cell death causing morphological changes detected by electron microscopy. As for LF, it did not affect DHA-induced cell death. Conclusion: The results demonstrated that ACT does not display enhanced anti-melanoma activity compared to artemisinin monotherapy. It suggests that AQ may have anti-oxidant properties, but would need to be explored further in the context of anti-oxidant cyto-protection.
3

Influences of first-line oral monotherapy on outcomes in Pulmonary Arterial Hypertension in association with Connective Tissue Disease.

Hamilton, Neil D. January 2013 (has links)
Background Pulmonary arterial hypertension (PAH) is a rare progressive disease with no known cure. Of various aetiologies, PAH in association with connective tissue disease (PAH-CTD) is the most rapidly progressive and difficult to treat. Management of PAH has evolved significantly in the past ten years since the introduction of oral therapies. Evidence for the efficacy of these agents outside randomised controlled trials is limited, but guidelines exist. Aim To measure the impact of first-line monotherapy with bosentan or sildenafil and the introduction of prescribing guidelines on outcomes in PAH-CTD. Methods Following a retrospective analysis of consecutive, incident, treatment-naive PAH-CTD cases identified by the ASPIRE registry, influences on outcome measures have been compared. First-line monotherapy episodes for 247 patients was analysed against four distinct endpoints: change in exercise capacity, WHO functional class, time on monotherapy and all-cause mortality. Results Treatment with bosentan or sildenafil resulted in clinical stability at 2 years for nearly 1/4 patients. No difference was identified between the groups in terms of either exercise capacity or WHO functional class. Sildenafil patients were found to remain on monotherapy longer than those prescribed bosentan. Patients prescribed sildenafil have improved survival over those treated with bosentan. Unexpected baseline differences in between groups may confound the results as the haemodynamics of the bosentan patients were more severe. Conclusions A significant number of patients with PAH-CTD remain clinically stable on monotherapy at 2 years. Both agents seem equally effective in this aggressive form of PAH. A novel endpoint “TOM” may be of value in future research assessing response to treatment.
4

Influences of first-line oral monotherapy on outcomes in Pulmonary Arterial Hypertension in association with Connective Tissue Disease

Hamilton, Neil David January 2013 (has links)
Background Pulmonary arterial hypertension (PAH) is a rare progressive disease with no known cure. Of various aetiologies, PAH in association with connective tissue disease (PAH-CTD) is the most rapidly progressive and difficult to treat. Management of PAH has evolved significantly in the past ten years since the introduction of oral therapies. Evidence for the efficacy of these agents outside randomised controlled trials is limited, but guidelines exist. Aim To measure the impact of first-line monotherapy with bosentan or sildenafil and the introduction of prescribing guidelines on outcomes in PAH-CTD. Methods Following a retrospective analysis of consecutive, incident, treatment-naive PAH-CTD cases identified by the ASPIRE registry, influences on outcome measures have been compared. First-line monotherapy episodes for 247 patients was analysed against four distinct endpoints: change in exercise capacity, WHO functional class, time on monotherapy and all-cause mortality. Results Treatment with bosentan or sildenafil resulted in clinical stability at 2 years for nearly 1/4 patients. No difference was identified between the groups in terms of either exercise capacity or WHO functional class. Sildenafil patients were found to remain on monotherapy longer than those prescribed bosentan. Patients prescribed sildenafil have improved survival over those treated with bosentan. Unexpected baseline differences in between groups may confound the results as the haemodynamics of the bosentan patients were more severe. Conclusions A significant number of patients with PAH-CTD remain clinically stable on monotherapy at 2 years. Both agents seem equally effective in this aggressive form of PAH. A novel endpoint “TOM” may be of value in future research assessing response to treatment.
5

A Meta-analytic Approach for Testing Evolutionary Hypotheses of Acquired Resistance in Metastatic Cancer

Bhardwaj, Kalpana 21 February 2014 (has links)
Nowell (1976) first proposed that unless cytotoxic cancer therapy eradicates all tumor cells, genetic or heritable variation within heterogeneous tumors will inevitably lead to the evolution of chemotherapeutic resistance through clonal selection. This evolutionary hypothesis was formalized by Goldie and Coldman (1979), who developed one of the earliest mathematical kinetic models of resistance evolution in neoplasms. Their model predicted that the likelihood of response and cure would be increased in combination vs single agent cytotoxic therapies. In a later study, Gardner (2002) developed a computational kinetic model to predict chemotherapeutic combinations, doses, and schedules most likely to result in patient response and prolonged life. This model predicts that combination therapy involving both cytotoxic and cytostatic drugs will be more effective than combination therapy involving only cytotoxic drugs. Thus far, no systematic evaluation of the Goldie and Coldman and Gardner hypotheses have been conducted in the metastatic clinical trial setting. Here I test these hypotheses using the results of over 700 phase II, III and II/III clinical trials. I show that, as predicted by Goldie and Coldman, both overall response rate and overall survival were greater in combination arms. Moreover, median duration of response – the key indicator of the rate of resistance evolution - was also greater in combination vs single agent arms. These results suggest that generally combination chemotherapy is more effective than single agent therapy for advanced solid tumors as predicted by Goldie and Coldman (1979) hypothesis and that, at least in the metastatic setting, the potential disadvantages of combination therapy with respect to accelerated resistance evolution are outweighed by the greater waiting times for resistance mutations to arise. By contrast, although combination cytotoxic and cytostatic therapy is associated with a greater average overall response rate than multi agent cytotoxic therapy, this is not the case for both median duration of response and overall survival. Hence, there is no evidence that, in contrast to the predictions of the Gardner (2002) model, combination cytotoxic and cytostatic therapy decreases the rate of resistance evolution relative to that obtaining under combination cytotoxic therapy.
6

A Meta-analytic Approach for Testing Evolutionary Hypotheses of Acquired Resistance in Metastatic Cancer

Bhardwaj, Kalpana January 2014 (has links)
Nowell (1976) first proposed that unless cytotoxic cancer therapy eradicates all tumor cells, genetic or heritable variation within heterogeneous tumors will inevitably lead to the evolution of chemotherapeutic resistance through clonal selection. This evolutionary hypothesis was formalized by Goldie and Coldman (1979), who developed one of the earliest mathematical kinetic models of resistance evolution in neoplasms. Their model predicted that the likelihood of response and cure would be increased in combination vs single agent cytotoxic therapies. In a later study, Gardner (2002) developed a computational kinetic model to predict chemotherapeutic combinations, doses, and schedules most likely to result in patient response and prolonged life. This model predicts that combination therapy involving both cytotoxic and cytostatic drugs will be more effective than combination therapy involving only cytotoxic drugs. Thus far, no systematic evaluation of the Goldie and Coldman and Gardner hypotheses have been conducted in the metastatic clinical trial setting. Here I test these hypotheses using the results of over 700 phase II, III and II/III clinical trials. I show that, as predicted by Goldie and Coldman, both overall response rate and overall survival were greater in combination arms. Moreover, median duration of response – the key indicator of the rate of resistance evolution - was also greater in combination vs single agent arms. These results suggest that generally combination chemotherapy is more effective than single agent therapy for advanced solid tumors as predicted by Goldie and Coldman (1979) hypothesis and that, at least in the metastatic setting, the potential disadvantages of combination therapy with respect to accelerated resistance evolution are outweighed by the greater waiting times for resistance mutations to arise. By contrast, although combination cytotoxic and cytostatic therapy is associated with a greater average overall response rate than multi agent cytotoxic therapy, this is not the case for both median duration of response and overall survival. Hence, there is no evidence that, in contrast to the predictions of the Gardner (2002) model, combination cytotoxic and cytostatic therapy decreases the rate of resistance evolution relative to that obtaining under combination cytotoxic therapy.
7

Avaliação da criptocococe experimental sistêmica em camundongos BALB/c e terapêutica com anfotericina B, fluconazol e associação. / Evaluation of experimental systemic cryptococcosis in BALB/c mice, and its treatment with amphotericin B and fluconazole, alone and in association.

Silva, Eriques Gonçalves da 16 October 2007 (has links)
A criptococose clinica foi observada por volta do primeiro dia da inoculação e a sobrevida dos animais 15 dias após-inoculação (PI). Isolamos C. neoformans no cérebro a partir do 5º dia (PI) e no pulmão a partir 11º dia (PI). No 1º dia (PI) observamos por meio do tecido cerebral que já havia um quadro inicial de infecção, presença de edema, que evoluiu durante todo o período. C. neoformans foi visualizado primeiramente nos vasos capilares, o que nos leva a sugerir que seja esta rota importante para a entrada da levedura no órgão. A meningite aguda aconteceu por volta do 7º dia quando visualizamos o microrganismo na meninge e com um discreto infiltrado inflamatório. A partir do 13º dia a doença evoluiu para crônica permanecendo até o óbito dos animais. A monoterapia com anfotericina B (AMB) reduziu a sobrevida dos animais, enquanto que, o tratamento isolado com fluconazol (FLC) prolongou a mesma. A associação AMB-FLC foi eficaz, quando iniciamos o tratamento 24 horas (PI), enquanto que, o mesmo tratamento iniciado a partir do 7º dia quando já tínhamos um quadro compatível de meningite aguda não foi satisfatório. É importante ressaltar que os resultados descritos foram referentes à inoculação com isolado sensível in vitro ao fluconazol, enquanto que, o tratamento não resultou em êxito quando empregamos isolado resistente in vitro ao fluconazol. / Clinical cryptococcosis was observed on day 1 postinoculation (PI), and the animals survived until day 15 PI. C. neoformans was isolated from brain tissue starting on day 5 PI, and from lung tissue starting on day 11 PI. On day 1 PI, signs of infection were already observed in brain tissue, with presence of edema, which evolved throughout the period. C. neoformans was first seen in the capillaries, suggesting that this is an important route for the entrance of the yeast into this organ. Acute meningitis occurred around day 7 PI, when the microorganism was observed in the meninges, along with a discrete inflammatory infiltrate. From day 13 PI onward the disease became chronic, persisting until the death of the animals. Treatment with amphotericin B (AMB) alone shortened the animals\' survival, while treatment with fluconazole (FLC) alone lengthened it. Treatment with the two drugs in association was effective when treatment was begun at 24 hours PI, however, when treatment was begun at day 7 PI, already with signs of acute meningitis, the effectiveness was unsatisfactory. It is important to emphasize that these results relate to inoculation with an isolate susceptible in vitro to fluconazole, while the treatment was not effective for an isolate resistant in vitro to fluconazole.
8

Avaliação da criptocococe experimental sistêmica em camundongos BALB/c e terapêutica com anfotericina B, fluconazol e associação. / Evaluation of experimental systemic cryptococcosis in BALB/c mice, and its treatment with amphotericin B and fluconazole, alone and in association.

Eriques Gonçalves da Silva 16 October 2007 (has links)
A criptococose clinica foi observada por volta do primeiro dia da inoculação e a sobrevida dos animais 15 dias após-inoculação (PI). Isolamos C. neoformans no cérebro a partir do 5º dia (PI) e no pulmão a partir 11º dia (PI). No 1º dia (PI) observamos por meio do tecido cerebral que já havia um quadro inicial de infecção, presença de edema, que evoluiu durante todo o período. C. neoformans foi visualizado primeiramente nos vasos capilares, o que nos leva a sugerir que seja esta rota importante para a entrada da levedura no órgão. A meningite aguda aconteceu por volta do 7º dia quando visualizamos o microrganismo na meninge e com um discreto infiltrado inflamatório. A partir do 13º dia a doença evoluiu para crônica permanecendo até o óbito dos animais. A monoterapia com anfotericina B (AMB) reduziu a sobrevida dos animais, enquanto que, o tratamento isolado com fluconazol (FLC) prolongou a mesma. A associação AMB-FLC foi eficaz, quando iniciamos o tratamento 24 horas (PI), enquanto que, o mesmo tratamento iniciado a partir do 7º dia quando já tínhamos um quadro compatível de meningite aguda não foi satisfatório. É importante ressaltar que os resultados descritos foram referentes à inoculação com isolado sensível in vitro ao fluconazol, enquanto que, o tratamento não resultou em êxito quando empregamos isolado resistente in vitro ao fluconazol. / Clinical cryptococcosis was observed on day 1 postinoculation (PI), and the animals survived until day 15 PI. C. neoformans was isolated from brain tissue starting on day 5 PI, and from lung tissue starting on day 11 PI. On day 1 PI, signs of infection were already observed in brain tissue, with presence of edema, which evolved throughout the period. C. neoformans was first seen in the capillaries, suggesting that this is an important route for the entrance of the yeast into this organ. Acute meningitis occurred around day 7 PI, when the microorganism was observed in the meninges, along with a discrete inflammatory infiltrate. From day 13 PI onward the disease became chronic, persisting until the death of the animals. Treatment with amphotericin B (AMB) alone shortened the animals\' survival, while treatment with fluconazole (FLC) alone lengthened it. Treatment with the two drugs in association was effective when treatment was begun at 24 hours PI, however, when treatment was begun at day 7 PI, already with signs of acute meningitis, the effectiveness was unsatisfactory. It is important to emphasize that these results relate to inoculation with an isolate susceptible in vitro to fluconazole, while the treatment was not effective for an isolate resistant in vitro to fluconazole.

Page generated in 0.0463 seconds